Trial Profile
Therapeutic effect and related factors of glecaprevir/pibrentasvir combination therapy for hepatitis C infected patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2020
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 08 Nov 2020 Status changed from recruiting to completed.
- 14 Nov 2018 New trial record